RE:RE:Woe are us.SPCEO1 wrote: The Cantor report was, at best, OK and got us a nice, semi-temporary pop higher. The Jones report was really well done but I have no familiarity with Jones and their capabilities to influence a share price. Clearly, the report had almost no influence on the share price yesterday. Maybe it takes a longer period of time for the report to make its way through Jones distribution network before it creates demand for the stock. With an institutional broker like Cantor, the effect is typically immediate as their own trading desk get active right away trading the stock. With a retail brokerage firm, their trading desk is likely less important and reaction to t he recommnedation of their analyst plays out over time as individual investors are sold on THTX by their advisors? I really don't know so I am just guessing.
But the Jones report was a good one and put some meat on the case for TH-1902. In the end, however, positive data from the phase 1b is what the stock needs to have a powerful and sustainable move higher. Having more and better analyst coverage when such news is hopefully released will help propel the move higher. But without positive news on TH-1902 or maybe a surprise resurrecction of NASH, or both, there is only so much agood analyst report can do, particularly in a bear market for biotech stocks.
longterm56 wrote: Markets up 2-4%, many stocks up 5-8%, long awaited "impressive" analyst report with a BUY and x3 price target ... THTX declines.
Merry Christmas?
-LT
There was no pop, this is normal downward trend of a stock, its like you have no clue, you just make things up on the spot. You've done this for years, you've made every possible excuse for this stock. You say you run a fund, you have destroyed peoples lives by being obsessed with this horrendous stock and managament. I just wanna ask you if you have any accountablity whatsoever?